Genentech to present new data from neuroscience portfolio at ECTRIMS

	The data from the neuroscience portfolio would be showed at the 35th ECTRIMS between September 11 and 13 in Stockholm.
	 
	The presentations would include entire Phase III outcomes from the SAkuraStar trial investigating satralizumab as a Neuromyelitis Optica Spectrum Disorder treatment.


Genentech, a biotechnology company and a subsidiary of Roche Group, reportedly announced that pivotal data from its neuroscience portfolio would be showcased in the 35th Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) between September 11 and 13 in Stockholm.

The presentations would include entire Phase III outcomes from the SAkuraStar trial investigating satralizumab for the treatment of Neuromyelitis Optica Spectrum Disorder, and latest Multiple Sclerosis research, which offers insights into progression of the disease, it comprises information from Ocrevus ® study that improve the understanding about Neurofilament Light Chain levels as a capable biomarker for forecasting disability results.

Furthermore, longer-term data of over six years to be proposed continue to show constant efficacy and safety outcomes for patients who took Ocrevus treatment previously.

Chief Medical Officer and Global Product Development Head at Genentech, Sandra Horning, M.D., stated that nervous system disorders are very difficult and complex to treat, and the company has grown its commitment towards neuroscience to enhance scientific understanding and care for conditions like Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis.

Horning added that data being shown at ECTRIMS also contains positive Phase III outcomes for satralizumab taken as a monotherapy, a novel approach for the treatment of Neuromyelitis Optica Spectrum Disorder, as well as novel insights utilizing biomarkers to recognize disease progression happening in multiple sclerosis. 

Horning also stated that similar to the company’s approach with Ocrevus regarding Multiple Sclerosis, aiming at B cells as the crucial driver of disease, the company aims to provide satralizumab as an effective Neuromyelitis Optica Spectrum Disorder treatment option.

 

Source credit:  https://www.gene.com/media/press-releases/14805/2019-09-03/genentech-to-present-pivotal-data-for-sa